Opus Genetics shared upbeat progress for its BEST1 gene therapy OPGx-BEST1, with phase I/II trial data supporting a path toward pivotal work in rare eye diseases caused by BEST1 mutations. The ongoing effort targets two conditions: Best vitelliform macular dystrophy and autosomal recessive bestrophinopathy, for which there is no approved therapy. The update suggests that the program is moving along the translational arc from early safety and signal-building toward later clinical endpoints. Investors will focus on how quickly the company can translate interim signals into a pivotal design. For retinal gene therapy, the key industry implication is continued evidence that carefully targeted programs for genetically defined subtypes can advance—provided trial readouts support efficacy and durability needed for regulatory and payer acceptance.